GLAND.NS Cash Flow
Gland Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹363.97 Cr. | ₹996.80 Cr. | ₹914.73 Cr. | ₹1,031.39 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹1,208.19 Cr. | ₹-1,756.91 Cr. | ₹1,704.74 Cr. | ₹137.73 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹14.92 Cr. | ₹-799.42 Cr. | ₹-433.48 Cr. | ₹-416.97 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹3.00 Cr. | ₹7.72 Cr. | ₹13.13 Cr. | ₹50.75 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹1,590.08 Cr. | ₹-1,551.81 Cr. | ₹2,199.12 Cr. | ₹802.90 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹318.82 Cr. | ₹1,908.89 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from GLAND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).